Polypharmacy cut-points in older people with cancer: how many medications are too many?

Supportive Care in Cancer

Volumn 24, Issue 4, 2016, Pages 1831-1840

  Turner, Justin P ^a,b,c   Jamsen, Kris M ^a,d   Shakib, Sepehr ^c   Singhal, Nimit ^c,e   Prowse, Robert ^c   Bell, J Simon ^a,b,d  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Aged; Cancer; Deprescribing; Polypharmacy

Indexed keywords

ANALGESIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTACID AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; RENIN INHIBITOR;

AGED; ARTICLE; COMORBIDITY; EXHAUSTION; FALLING; FEMALE; FRAIL ELDERLY; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; NEOPLASM; ONCOLOGY; OUTPATIENT DEPARTMENT; PHYSICAL CAPACITY; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VERY ELDERLY; CHEMICALLY INDUCED; EVALUATION STUDY; FATIGUE; GERIATRIC ASSESSMENT; NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STANDARD; STATISTICS AND NUMERICAL DATA;

ACCIDENTAL FALLS; AGED; AGED, 80 AND OVER; COMORBIDITY; FATIGUE; FEMALE; GERIATRIC ASSESSMENT; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; NEOPLASMS; POLYPHARMACY; REFERENCE STANDARDS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84959169222     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-015-2970-8     Document Type: Article

References (51)

1. Tromp AM, Pluijm SM, Smit JH, Deeg DJ, Bouter LM, Lips P (2001) Fall-risk screening test: a prospective study on predictors for falls in community-dwelling elderly. J Clin Epidemiol 54:837–844
2. Marcum ZA, Amuan ME, Hanlon JT, Aspinall SL, Handler SM, Ruby CM, Pugh MJ (2012) Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans. J Am Geriatr Soc 60:34–41. doi:10.1111/j.1532-5415.2011.03772.x
3. Jyrkka J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S (2009) Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging 26:1039–1048. doi:10.2165/11319530
4. Williams GR, Deal AM, Nyrop KA, Pergolotti M, Guerard EJ, Jolly TA, Muss HB (2015) Geriatric assessment as an aide to understanding falls in older adults with cancer. Support Care Cancer 23:2273–2280. doi:10.1007/s00520-014-2598-0
5. Turner JP, Shakib S, Singhal N, Hogan-Doran J, Prowse R, Johns S, Bell JS (2014) Prevalence and factors associated with polypharmacy in older people with cancer. Support Care Cancer 22:1727–1734. doi:10.1007/s00520-014-2171-x
6. Balducci L, Goetz-Parten D, Steinman MA (2013) Polypharmacy and the management of the older cancer patient. Ann Oncol 24(Suppl 7):vii36–vii40. doi:10.1093/annonc/mdt266
7. Tam-McDevitt J (2008) Polypharmacy, aging, and cancer. Oncology 22:1052–1055
8. Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, McLachlan AJ, Cumming RG, Handelsman DJ, Le Couteur DG (2012) Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 65:989–995. doi:10.1016/j.jclinepi.2012.02.018
9. Veehof L, Stewart R, Haaijer-Ruskamp F, Jong BM (2000) The development of polypharmacy. A longitudinal study. Fam Pract 17:261–267
10. Iliffe S, Haines A, Gallivan S, Booroff A, Goldenberg E, Morgan P (1991) Assessment of elderly people in general practice. 2. Functional abilities and medical problems. Br J Gen Pract 41:13–15
11. Beloosesky Y, Nenaydenko O, Gross Nevo RF, Adunsky A, Weiss A (2013) Rates, variability, and associated factors of polypharmacy in nursing home patients. Clin Interv Aging 8:1585–1590. doi:10.2147/CIA.S52698
12. Morris J, Hawes C, Murphy K, Nonemaker S, Philips C, Fries B, Mor V (1991) Minimum data set resident assessment instrument training manual and resource guide. Elliot Press, Natick
13. Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Cumming RG, Handelsman DJ, McLachlan AJ, Abernethy DR, Banks E, Le Couteur DG (2012) High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther 91:521–528. doi:10.1038/clpt.2011.258
14. Gilbert AL, Roughead EE, Beilby J, Mott K, Barratt JD (2002) Collaborative medication management services: improving patient care. Med J Aust 177:189–192
15. Lakhanpal R, Yoong J, Joshi S, Yip D, Mileshkin L, Marx GM, Dunlop T, Hovey EJ, Della Fiorentina SA, Venkateswaran L, Tattersall MHN, Liew S, Field K, Singhal N, Steer CB (2015) Geriatric assessment of older patients with cancer in Australia—A multicentre audit. J Geriatr Oncol. doi:10.1016/j.jgo.2015.03.001
16. Hovstadius B, Astrand B, Petersson G (2009) Dispensed drugs and multiple medications in the Swedish population: an individual-based register study. BMC Clin Pharmacol 9:11. doi:10.1186/1472-6904-9-11
17. Corcoran ME (1997) Polypharmacy in the older patient with cancer. Cancer Control 4:419–428
18. Hurria A, Browner IS, Cohen HJ, Denlinger CS, deShazo M, Extermann M, Ganti AK, Holland JC, Holmes HM, Karlekar MB, Keating NL, McKoy J, Medeiros BC, Mrozek E, O'Connor T, Petersdorf SH, Rugo HS, Silliman RA, Tew WP, Walter LC, Weir AB 3rd, Wildes T (2012) Senior adult oncology. J Natl Compr Cancer Netw 10:162–209
19. Kojima T, Akishita M, Nakamura T, Nomura K, Ogawa S, Iijima K, Eto M, Ouchi Y (2012) Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int 12:425–430. doi:10.1111/j.1447-0594.2011.00783.x
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
21. Orme JG, Reis J, Herz EJ (1986) Factorial and discriminant validity of the Center for Epidemiological Studies Depression (CES-D) scale. J Clin Psychol 42:28–33
22. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA, Cardiovascular Health Study Collaborative Research Group (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146–M156. doi:10.1093/gerona/56.3.M146
23. Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 30(6):473–483
24. Fillenbaum GG, Smyer MA (1981) The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. J Gerontol 36:428–434
25. Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: C.M. M (ed) Evaluation of chemotherapeutic agents. Columbia University Press, pp. 196.
26. WHO Collaborating Centre for Drug Statistics Methodology (2011) Guidelines for ATC classification and DDD assignment, 2012., Oslo
27. Hurria A, Gupta S, Zauderer M, Zuckerman EL, Cohen HJ, Muss H, Rodin M, Panageas KS, Holland JC, Saltz L, Kris MG, Noy A, Gomez J, Jakubowski A, Hudis C, Kornblith AB (2005) Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 104:1998–2005. doi:10.1002/cncr.21422
28. Ruopp MD, Perkins NJ, Whitcomb BW, Schisterman EF (2008) Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom J 50:419–430. doi:10.1002/bimj.200710415
29. Cook NR (2007) Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115:928–935. doi:10.1161/CIRCULATIONAHA.106.672402
30. Santoni G, Angleman S, Welmer AK, Mangialasche F, Marengoni A, Fratiglioni L (2015) Age-related variation in health status after age 60. PLoS One 10:e0120077. doi:10.1371/journal.pone.0120077
31. Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A, De Cataldis G, Iannelli A, Bilancia D, Belli M, Massidda B, Piantedosi F, Comella G, De Lena M (2000) Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18:2529–2536
32. R Core Team (2013) R: a language and environment for statistical computing. R Development Core Team, Vienna, Austria, URL http://www.R-project.org/
33. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinf 12:77. doi:10.1186/1471-2105-12-77
34. Jorgensen T, Herrstedt J, Friis S, Hallas J (2012) Polypharmacy and drug use in elderly Danish cancer patients during 1996 to 2006. J Geriatr Oncol 3:33–40
35. Saarelainen LK, Turner JP, Shakib S, Singhal N, Hogan-Doran J, Prowse R, Johns S, Lees J, Bell JS (2014) Potentially inappropriate medication use in older people with cancer: prevalence and correlates. J Geriatr Oncol 5:439–446. doi:10.1016/j.jgo.2014.07.001
36. Koponen MP, Bell JS, Karttunen NM, Nykänen IA, Desplenter FA, Hartikainen SA (2013) Analgesic use and frailty among community-dwelling older people: a population-based study. Drugs Aging 30:129–136. doi:10.1007/s40266-012-0046-8
37. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW (2005) Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 294:716–724. doi:10.1001/jama.294.6.716
38. Payne RA, Abel GA, Avery AJ, Mercer SW, Roland MO (2014) Is polypharmacy always hazardous?A retrospective cohort analysis using linked electronic health records from primary and secondary care. Br J Clin Pharmacol. doi:10.1111/bcp.12292
39. Yeoh TT, Si P, Chew L (2013) The impact of medication therapy management in older oncology patients. Support Care Cancer 21:1287–1293. doi:10.1007/s00520-012-1661-y
40. Cashman J, Wright J, Ring A (2010) The treatment of co-morbidities in older patients with metastatic cancer. Support Care Cancer 18:651–655
41. American Geriatrics Society Beers Criteria Update Expert P (2012) American geriatrics society updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 60:616–631. doi:10.1111/j.1532-5415.2012.03923.x
42. Taipale HT, Bell JS, Gnjidic D, Sulkava R, Hartikainen S (2012) Sedative load among community-dwelling people aged 75 years or older: association with balance and mobility. J Clin Psychopharmacol 32:218
43. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P (2015) STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 44:213–218. doi:10.1093/ageing/afu145
44. Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, Cohen HJ, Feussner JR (1992) A method for assessing drug therapy appropriateness. J Clin Epidemiol 45:1045–1051
45. Reeve E, Wiese MD, Hendrix I, Roberts MS, Shakib S (2013) People's attitudes, beliefs, and experiences regarding polypharmacy and willingness to deprescribe. J Am Geriatr Soc 61:1508–1514
46. Maddison AR, Fisher J, Johnston G (2011) Preventive medication use among persons with limited life expectancy. Prog Palliat Care 19:15
47. Lees J, Toh B (2009) Does a pharmacist derived medication history (MH) provide more information than a geriatric cancer patient-completed medication list, and does it matter? Asia Pac J Clin Oncol 5(Suppl 2):A176
48. Lau HS, Florax C, Porsius AJ, De Boer A (2001) The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards. Br J Clin Pharmacol 49:597–603. doi:10.1046/j.1365-2125.2000.00204.x
49. Lees J (2013) Management of polypharmacy in older cancer patients. Cancer Forum 37:230–233
50. Belfrage B, Koldestam A, Sjoberg C, Wallerstedt SM (2015) Number of drugs in the medication list as an indicator of prescribing quality: a validation study of polypharmacy indicators in older hip fracture patients. Eur J Clin Pharmacol 71:363–368. doi:10.1007/s00228-014-1792-9
51. Kuijpers MAJ, Van Marum RJ, Egberts ACG, Jansen PAF (2007) Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol 65:130–133